SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease

Experimental Neurology

Volumn 184, Issue 1, 2003, Pages 436-446

  Pountney, D L ^a   Huang, Y ^a   Burns, R J ^b   Haan, E ^c   Thompson, P D ^d   Blumbergs, P C ^e   Gai, W P ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b Flinders Private Hospital   (Australia)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Neuronal intranuclear inclusion disease; Nuclear body; Nuclear inclusion; Polyglutamine; Proteasome; SUMO 1

Indexed keywords

PROTEASOME; SUMO 1 PROTEIN;

AGED; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CASE REPORT; CELL NUCLEUS INCLUSION BODY; CLINICAL FEATURE; CONJUGATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; ELECTRON MICROSCOPY; FAMILIAL DISEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; NEURONAL INTRANUCLEAR INCLUSION DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

EID: 0344826098     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.07.004     Document Type: Article

References (52)

1. Andersen J.S., Lyon C.E., Fox A.H., Leung A.K., Lam Y.W., Steen H., Mann M., Lamond A.I. Directed proteomic analysis of the human nucleolus. Curr. Biol. 12:2002;1-11.
2. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555.
3. Best J.L., Ganiatsas S., Agarwal S., Changou A., Salomoni P., Shirihai O., Meluh P.B., Pandolfi P.P., Zon L.I. SUMO-1 protease-1 regulates gene transcription through PML. Mol. Cell. 10:2002;843-855.
4. Boisvert F.M., Kruhlak M.J., Box A.K., Hendzel M.J., Bazett-Jones D.P. The transcription coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body. J. Cell Biol. 152:2001;1099-1106.
5. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 299:2003;256-259.
6. Desterro J.M., Rodriguez M.S., Hay R.T. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol. Cell. 2:1998;233-239.
7. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1997;1990-1993.
8. Duyckaerts C., Durr A., Cancel G., Brice A. Nuclear inclusions in spinocerebellar ataxia type 1. Acta Neuropathol. 97:1999;201-207.
9. Eskiw C.H., Bazett-Jones D.P. The promyelocytic leukemia nuclear body sites of activity? Biochem. Cell Biol. 80:2002;301-310.
10. Fogal V., Gostissa M., Sandy P., Zacchi P., Sternsdorf T., Jensen K., Pandolfi P.P., Will H., Schneider C., Del Sal G. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19:2000;6185-6195.
11. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway destruction for the sake of construction. Physiol. Rev. 82:2002;373-428.
12. Haltia M., Tarkkanen A., Somer H., Palo J., Karli H. Neuronal intranuclear inclusion disease clinical ophthalmological features and ophthalmic pathology. Acta Ophthalmol. 64:1986;637-643.
13. Hay R.T. Protein modification by SUMO. Trends Biochem. Sci. 26:2001;332-333.
14. Hodges M., Tissot C., Howe K., Grimwade D., Freemont P.S. Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. Am. J. Hum. Genet. 63:1998;297-304.
15. Iseki E., Odawara T., Li F., Kosaka K., Nishimura T., Akiyama H., Ikeda K. Age-related ubiquitin-positive granular structures in non-demented subjects and neurodegenerative disorders. J. Neurol. Sci. 142:1996;25-29.
16. Janota I. Widespread intranuclear neuronal corpuscles (Marinesco bodies) associated with a familial spinal degeneration with cranial and nerve involvement. Neuropathol. Appl. Neurobiol. 5:1979;311-317.
17. Jentsch S., Pyrowolakis G. Ubiquitin and its kin how close are the family ties? Trends Cell Biol. 10:2000;335-342.
18. Kannan K., Kaminski N., Rechavi G., Jakob-Hirsch J., Amariglio N., Givol D. DNA microarray analysis of genes involved in P53 mediated apoptosis activation of Apaf-1. Oncogene. 20:2001;3449-3455.
19. Kim K.I., Baek S.H., Jeon Y.-J., Nishimori S., Suzuki T., Uchida S., Shimbara N., Saitoh H., Tanaka K., Chung C.H. A new SUMO-1-specific protease, SUSP1, that is highly expressed in reproductive organs. J. Biol. Chem. 275:2000;14102-14106.
20. Kimber T.E., Blumbergs P.C., Rice J.P., Hallpike J.F., Edis R., Thompson P.D., Suthers G. Familial neuronal intranuclear inclusion disease with ubiquitin positive inclusions. J. Neurol. Sci. 160:1998;33-40.
21. Lafarga M., Berciano M.T., Pena E., Mayo I., Castano J.G., Bohmann D., Rodrigues J.P., Tavanez J.P., Carmo-Fonseca M. Clastosome a subtype of nuclear body enriched in 19S and 20S proteasomes, ubiquitin, and protein substrates of proteasome. Mol. Biol. Cell. 13:2002;2771-2782.
22. Lieberman A.P., Robitaille Y., Trojanowski J.Q., Dickson D.W., Fishbeck K.H. Polyglutamine-containing aggregates in neuronal intranuclear inclusion disease. Lancet. 351:1998;884.
23. Lieberman A.P., Trojanowski J.Q., Leonard D.G., Chen K.L., Barnett J.L., Leverenz J.B., Bird T.D., Robitaille Y., Malandrini A., Fishbeck K.H. Ataxin 1 and ataxin 3 in neuronal intranuclear inclusion disease. Ann. Neurol. 46:1999;271-273.
24. Lindenberg R., Rubinstein L.J., Herman M.M., Haydon G.B. A light and electron microscopy study of an unusual widespread nuclear inclusion body disease. A possible residuum of an old herpesvirus infection. Acta Neuropathol. 10:1968;54-73.
25. Mahajan R., Gerace L., Melchior F. Molecular characterization of the SUMO-1 modification of RanGAP1 and its role in nuclear envelope association. J. Cell Biol. 140:1998;259-270.
26. Mattsson K., Pokrovskaja K., Kiss C., Klein G., Szekely L. Proteins associated with the promyelocytic leukemia gene product (PML)-containing nuclear body move to the nucleolus upon inhibition of proteasome-dependent protein degradation. Proc. Natl. Acad. Sci. USA. 98:2001;1012-1017.
27. McCampbell A., Taylor J.P., Taye A.A., Robischek J., Li M., Walcott J., Merry D., Chai Y., Paulson H., Sobue G., Fischbeck K. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 9:2000;2197-2202.
28. McClean P.J., Kawamata H., Hyman B.T. α-Synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive incusions in primary neurons. Neuroscience. 104:2001;901-912.
29. Melchior F. SUMO - nonclassical ubiquitin. Annu. Rev. Cell Dev. Biol. 16:2000;591-626.
30. Muller S., Hoege C., Pyrowolakis G., Jentsch S. SUMO, ubiquitin's mysterious cousin. Nat. Rev. Mol. Cell Biol. 2:2001;202-210.
31. Nishida T., Kaneko F., Kitagawa M., Yasuda H. Characterization of a novel mammalian SUMO/Smt3-specific isopeptidase, a homologue of rat Axam, which is an Axin-binding protein promoting b-catenin degradation. J. Biol. Chem. 276:2001;39060-39066.
32. Nollen E.A., Salomons F.A., Brunsting J.F., Want J.J., Sibon O.C., Kampinga H.H. Dynamic changes in the localization of thermally unfolded nuclear proteins associated with chaperone-dependent protection. Proc. Natl. Acad. Sci. USA. 98:2001;12038-12043.
33. O'Sullivan J.D., Hanagasi H.A., Daniel S.E., Tidswell P., Davies S.W., Lees A.J. Neuronal intranuclear inclusion disease and juvenile parkinsonism. Mov. Disord. 15:2000;990-995.
34. Paulson H.L., Bonini N.M., Roth K.A. Polyglutamine disease and neuronal cell death. Proc. Nat. Acad. Sci. USA. 97:2000;12957-12958.
35. Paulson H.L., Das S.S., Crino P.B., Perez M.K., Patel S.C., Gotsdiner D., Fishbeck K.H., Pittman R.N. Machado-Joseph Disease Gene Product is a cytoplasmic protein widely expressed in brain. Ann. Neurol. 41:1997;453-462.
36. Paulson H.L., Perez M.K., Trottier Y., Trojanowski J.Q., Subramony S.H., Das S.S., Vig P., Mandel J.-L., Fishbeck K.H., Pittman R.N. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron. 19:1997;333-344.
37. Perez M.K., Paulson H.L., Pittman R.N. Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix. Hum. Mol. Genet. 8:1999;2377-2385.
38. Pountney, D.L., Blumbergs, P.C., Gai, W.P., (2002). Neuropathological Intranuclear Protein Aggregates Containing SUMO-1 Modified Ataxin-3 with Exposed Polyglutamine. The 27th Annual Lorne Conference on Protein Structure and Function, Lorne, Australia, ISSN 1034-3180, C-7.
39. Rideout H.J., Larsen K.E., Sulzer D., Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 8:2001;899-908.
40. Sampson D.A., Wang M., Matunis M.J. The SUMO-1 consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J. Biol. Chem. 276:2001;21664-21669.
41. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins a cell biologist thinks about neurodegenerative diseases. Neuron. 29:2001;15-32.
42. Stevanin G., Durr A., Brice A. Spinocerebellar ataxias caused by polyglutamine expansions. Adv. Exp. Med. Biol. 516:2002;47-77.
43. Subramanian L., Benson M.D., Iniguez-Lluhi J.A. A synergy control motif within the attenuator domain of C/EBPalpha inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3. J. Biol. Chem. 278:2003;9134-9141.
44. Szebeni A., Olson M.O. Nucleolar protein B23 has molecular chaperone activities. Protein Sci. 8:1999;905-912.
45. Takahashi J., Junici T., Arai K., Funata N. Recruitment of non-expanded polyglutamine proteins to intranuclear aggregates in neuronal intranuclear hyaline inclusion disease. J. Neuropathol. Exp. Neurol. 60:2001;369-375.
46. Terashima T., Kawai H., Fujitani M., Maeda K., Yasuda H. SUMO-1 co-localized with mutant atrophin-1 with expanded polyglutamines accelerates intranuclear aggregation and cell death. Neuroreport. 13:2002;2359-2364.
47. Torii S., Egan D.A., Evans R.A., Reed J.C. Human Daxx regulates Fas induced apoptosis from nuclear PML oncogenic domains (PODs). EMBO J. 18:1997;6037-6049.
48. Ueda H., Goto J., Hashida H., Lin X., Oyanagi K., Kawano H., Zoghbi H.Y., Kanazawa I., Okazawa H. Enhanced SUMOylation in polyglutamine diseases. Biochem. Biophys. Res. Commun. 293:2002;307-313.
49. Waelter S., Boeddrich A., Lurz R., Scherzinger E., Lueder G., Lehrach H., Wanker E.E. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell. 12:2001;1393-1407.
50. Weidenheim K.M., Dickson D.W. Intranuclear inclusion bodies in an elderly demented woman a form of intranuclear inclusion body disease. Clin. Neuropathol. 14:1995;93-99.
51. Zannolli R., Gilman S., Rossi S., Volpi N., Bernini A., Galluzzi P., Galimberti D., Pucci L., D'Ambrosio A., Morgese G., Giannini F. Hereditary neuronal intranuclear inclusion disease with autonomic failure and cerebellar degeneration. Arch. Neurol. 59:2002;1319-1326.
52. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23:2000;217-247.